
## Figure S2



**Figure S2.** Characterization of m<sup>6</sup>A changes and FTO expression in different cell types. **a** Coverage plots of m<sup>6</sup>A IP and input reads (without smoothing the curve). Examples of differentially methylated transcripts harboring m<sup>6</sup>A peaks exposing to nilotinib are shown. **b** IGV tracks displaying examples of sequencing read clusters from two m<sup>6</sup>A-seq replicates are shown. **c** Coverage plots of m<sup>6</sup>A IP and input reads (without smoothing the curve). **d,e** IGV tracks displaying examples of sequencing read clusters from two m<sup>6</sup>A-seq replicates are shown. **f** Western blotting (left) and dotblotting (right) of K562 parental, nilotinibR and released cells. **g** Western blot for FTO expression. The resistant cells were cultured in drug-containing or drug-free medium for 15 days. The parental cells were used as controls.

IP, immunoprecipitation; IN, input; P, parental; N (Nilo), nilotinibR; R, reacquired sensitivity (released); In  $\mathbf{b}$ ,  $\mathbf{d}$  and  $\mathbf{e}$ , IP = blue, Input = red.